Dec 29, 2022 8:30am EST 180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
Dec 23, 2022 8:00am EST 180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Dec 20, 2022 2:11pm EST 180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Dec 16, 2022 9:00am EST 180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan
Nov 30, 2022 5:00pm EST 180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture
Nov 21, 2022 8:30am EST 180 Life Sciences to Participate in A.G.P.’s Virtual Biotech Conference to be Held November 30 – December 1, 2022
Nov 15, 2022 12:37pm EST CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
Nov 15, 2022 8:00am EST Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
Aug 22, 2022 8:30am EDT 180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder